Research site

Melbourne, Victoria 3181

2 studies enrolling now · 28 studies all time

What they study most

Acute Coronary Syndrome, Acute Myeloid Leukemia, Advanced Malignancy, Advanced Solid Tumors, Atypical Hemolytic Uremic Syndrome (aHUS), B-Cell Non Hodgkin Lymphoma, Cancer, Carcinoma of the Head and Neck, Generalized Myasthenia Gravis (gMG), Hemophilia A, Hepatobiliary Cancers, Hypercholesterolemia

Studies at this site

• Observational Study Protocol: LIVER-R — Recruiting now
• Study of Ultomiris® (Ravulizumab) Safety in Pregnancy — Recruiting now
• DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — Completed
• Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma — Stopped early
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) — Completed
• A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma — Completed
• Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL — Completed
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A — Completed
• Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A — Completed
• Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale — Completed
• An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 — Completed
• A Multicenter Assessment of ALD403 in Chronic Migraine — Completed
• Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients — Completed
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia — Completed
• GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound — Completed
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) — Completed
• BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis — Stopped early
• BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis — Stopped early
• 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms — Stopped early
• A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome — Completed